Investigational New Drugs投稿须知

期刊简介

《Investigational New Drugs》是由Springer US出版社于1983年创办的英文国际期刊（ISSN: 0167-6997，E-ISSN: 1573-0646），该期刊长期致力于药学领域的创新研究，主要研究方向为医学-药学。作为SCIE收录期刊（JCR分区 Q2，中科院 3区），本刊采用OA未开放获取模式（OA占比0.1962...%），以发表药学领域等方向的原创性研究为核心（研究类文章占比94.25%%）。凭借严格的同行评审与高效编辑流程，期刊年载文量精选控制在87篇，确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库，为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Investigational New Drugs审稿周期约为约1.0个月。该刊近年未被列入国际预警名单，年发文量约87篇，录用竞争适中，主题需确保紧密契合医学前沿。投稿策略提示：避开学术会议旺季投稿以缩短周期，语言建议专业润色提升可读性。

医学大类学科
English 出版语言
否是否预警
SCIE 期刊收录
87 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊	综述期刊	大类学科	小类学科
否	否	医学 3区	PHARMACOLOGY & PHARMACY 药学 ONCOLOGY 肿瘤学 3区 4区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊	综述期刊	大类学科	小类学科
否	否	医学 3区	PHARMACOLOGY & PHARMACY 药学 ONCOLOGY 肿瘤学 3区 4区

JCR分区

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q2	142 / 322	56.1%
学科：PHARMACOLOGY & PHARMACY	SCIE	Q2	136 / 354	61.7%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q2	98 / 322	69.72%
学科：PHARMACOLOGY & PHARMACY	SCIE	Q2	111 / 354	68.79%

CiteScore

SJR

SNIP

CiteScore 排名

CiteScore：7.6

SJR：1.086

SNIP：0.678

学科类别	分区	排名	百分位
大类：Medicine 小类：Pharmacology (medical)	Q1	43 / 272	84%
大类：Medicine 小类：Oncology	Q1	88 / 404	78%
大类：Medicine 小类：Pharmacology	Q2	80 / 313	74%

期刊发文

The influence of verapamil on the pharmacokinetics of the pan-HER tyrosine kinase inhibitor neratinib in rats: the role of P-glycoprotein-mediated efflux
Author: Qi, Defei; Dou, Yuanyuan; Zhang, Wenke; Wang, Mengqing; Li, Yingying; Zhang, Mingzhu; Qin, Jia; Cao, Jinlan; Fang, Dong; Ma, Jing; Yang, Wei; Xie, Songqiang; Sun, Hua

Journal: INVESTIGATIONAL NEW DRUGS. 2023; Vol. 41, Issue 1, pp. 13-24. DOI: 10.1007/s10637-022-01314-7
Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE)
Author: Qian, Kun; Chen, Qi-Rui; He, Ming; Wang, Zi-Tong; Liu, Yu; Liang, Hua-Gang; Su, Zhi-Yong; Cui, Yu-Shang; Liu, Li-Jun; Zhang, Yi

Journal: INVESTIGATIONAL NEW DRUGS. 2023; Vol. 41, Issue 1, pp. 44-52. DOI: 10.1007/s10637-022-01316-5
Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions
Author: Liu, Zhengzhi; Xu, Zhongnan; Gao, Zhenyue; Ren, Qing; Chang, Tianying; Xue, Jinling; Yang, Haimiao

Journal: INVESTIGATIONAL NEW DRUGS. 2023; Vol. 41, Issue 1, pp. 60-69. DOI: 10.1007/s10637-022-01320-9
Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China
Author: Hou, Helei; Wang, Yongjie; Sun, Dantong; Zhu, Jingjuan; Jiang, Man; Zhang, Xuchen; Zhou, Na; Zhang, Chuantao; Li, Tianjun; Zhang, Xiaochun

Journal: INVESTIGATIONAL NEW DRUGS. 2023; Vol. 41, Issue 1, pp. 86-92. DOI: 10.1007/s10637-022-01324-5
Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study
Author: Jia, Dong-Dong; Xu, Yu; Li, Ting; Yang, Ji-Long; Chen, Yong; Li, Tao

Journal: INVESTIGATIONAL NEW DRUGS. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10637-023-01348-5
Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase
Author: Zhang, Chan; Zhao, Xinan; Wang, Zifeng; Gong, Tao; Zhao, Hong; Zhang, Dong; Niu, Yuhu; Li, Xiaoning; Zhao, Xuhua; Li, Gaopeng; Dong, Xiushan; Zhang, Li; Liu, Chang; Xu, Jun; Yu, Baofeng

Journal: INVESTIGATIONAL NEW DRUGS. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10637-023-01360-9
Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma
Author: Hu, Shiqi; Liu, Yaqin; Yang, Qidong; Chen, Lin; Chai, Huizi; Xiao, Mingzhe; Qi, Chuang; Qiu, Wei

Journal: INVESTIGATIONAL NEW DRUGS. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10637-023-01363-6
Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells
Author: Yan, Gaobo; Zhang, Hongyan; Li, Yan; Miao, Guoqiang; Liu, Xiaolei; Lv, Qifan

Journal: INVESTIGATIONAL NEW DRUGS. 2023; Vol. 41, Issue 1, pp. 134-141. DOI: 10.1007/s10637-023-01330-1

Investigational New Drugs

研究性新药

期刊简介

投稿提示

中科院分区

JCR分区

CiteScore

期刊发文

相关期刊

怎样选择期刊

投稿相关问题

投稿后咨询